MPD2

MPD2 (0.1-10 μM; 48 h) significantly reduces the level of M^Pro-eGFP fusion protein in stably transfected 293T cells in a concentration-dependent manner, and this result is confirmed by flow cytometry analysis[1].
MPD2 (0.03-3 μM; 48 h) exhibits potent activity to induce M^Pro degradation in M^Pro-eGFP stably transfected 293T cells, with a DC₅₀ value of 296 nM as determined by Western blot analysis[1].
MPD2 (0.3-3 μM; 48 h) induces M^Pro degradation via a CRBN-mediated, proteasome-dependent mechanism that requires simultaneous binding to both M^pro and CRBN, as confirmed by competition experiments with MPI8 and pomalidomide and CRISPR-mediated CRBN knockout studies^[1].
MPD2 (0.1-3 μM; 48 h) degrades M^Pro in a proteasome-dependent manner^[1].
MPD2 (72 h) exhibits the most potent antiviral activity against the SARS-CoV-2 Delta variant in ACE2⁺ A549 cells, with an EC₅₀ value of 492 nM, and demonstrates the strongest capacity to reduce M^Pro protein levels among the tested PROTAC degraders, correlating with its superior antiviral efficacy^[1].
MPD2 (0.63-10 μM; 48 h) exhibits broad-spectrum antiviral efficacy against SARS-CoV-2 variants WA.1, BA.1, and XBB.1.5, reducing viral production by 90% in infected A549-hACE2 cells at a concentration of 2.5 μM^[1].
MPD2 (48 h) demonstrates 5-fold greater potency against the nirmatrelvir-resistant NSP5 E166A mutant SARS-CoV-2 compared with the wild-type virus, with gradient concentrations tested over 48 hours of treatment^[1].
MPD2 (48 h) exhibits significantly lower cytotoxicity in 293T cells, with a CC₅₀ value of 120 μM as determined by MTT assay, which is even higher than the CC₅₀ value (70 μM) of the parent MPI8[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.